1. Scrip

Immunocore Ready For First-Ever Launch After Kimmtrak’s US Approval

European Approval And Launch Also Expected Soon

 
• By Mandy Jackson

The median pre-discount cost of Kimmtrak – the first approved TCR therapy and the first drug cleared for metastatic uveal melanoma – is $430,000, but the company says payers see the product’s value.

Brave new world concept of boy running with kite towards sunset sea horizon
Immunocore has profiled most of the relevant prescribers and payers ahead of its first US drug launch • Source: Alamy

Immunocore, Ltd. achieved several firsts with the US Food and Drug Administration approval of Kimmtrak (tebentafusp-tebn) – it is the first approved T-cell receptor (TCR) therapy, the first drug approved for metastatic uveal melanoma and Immunocore’s first approved product. But executives said in a same-day conference call that Immunocore is ready for its first-ever commercial launch.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip